 |
|
|
Experimental Strategies for Biomarker Discovery and Development
|
|
|
|
|
Event Recorded on:
|
|
Wednesday, 22 August 2007, 11:00 AM - 12:00 PM
(GMT -07:00) Pacific Time (US & Canada); Tijuana
|
|
|
|
|
Abstract
Typical biomarker studies can be divided into four phases: discovery, validation, purification and identification, and assay development. We will discuss these phases and present approaches to optimizing biomarker workflows to deliver robust biomarkers and biomarker assays. Case studies using the Bio-Rad ProteinChip® SELDI system in both preclinical and clinical areas will be presented to illustrate optimized biomarker workflows.
In the discovery and validation phases, it is especially important to optimize study design and statistical methods to avoid pre-analytical bias and yield robust markers. Identification can be performed at the end of the discovery phase or at any point during the validation phase and generally requires standard protein purification procedures (column chromatography, size filtration, SDS-PAGE, etc.), followed by protease digestion and sequence analysis on a tandem mass spectrometer. Identification of the biomarkers provides insight into disease biology and facilitates the development of analyte-specific assays. Once the biomarkers have been positively identified, quantitative assays can be developed for routine testing on an appropriate immunoassay platform (SELDI, Bio-Plex® suspension array system, or ELISA). SELDI-based immunoassays are particularly useful for detecting biomarkers with posttranslational modifications.
About the Speaker
|
|
|
|
Diane McCarthy, PhD
|
Dr. McCarthy oversees the operation of Bio-Rad's Biomarker Research Centers. She received her PhD in biochemistry from The University of Texas at Austin and completed a postdoctoral fellowship focused on protein expression, purification, and structural analysis. She has over five years' experience managing biomarker research collaborations with leading academic groups (including the National Cancer Institute and Johns Hopkins University) and pharmaceutical companies (including publicly disclosed collaborations with Novartis, Bayer, and sanofi-aventis).
About ProteinChip SELDI Technology:
SELDI (surface-enhanced laser desorption/ionization) combines the separation power of chromatography with the sensitivity of mass spectrometry for rapid, content-rich, proteomic analysis of complex biological samples including serum, urine, cerebrospinal fluid, and cell and tissue lysates. The SELDI approach utilizes chromatographic ProteinChip arrays (e.g., reverse phase, anion and cation exchange, metal affinity) coupled with different binding conditions to capture and enrich proteins with specific biochemical properties and increase the total number of detectable species. Washing of the arrays removes nonspecifically bound proteins and interfering compounds, greatly reducing signal suppression in the mass spectrometer caused by salts and detergents. Bio-Rad’s ProteinChip SELDI system is a high-throughput, reproducible platform for biomarker research. This reliable technology has been used throughout the world to discover and characterize biomarkers for research in oncology, neurobiology, infectious disease, and toxicology.
*Note: This webinar utilizes Internet audio. Please make sure that your system has audio capabilities before attending.
|
|
|
|
|
|
|